Log in

NASDAQ:AKCA - Akcea Therapeutics Stock Price, Forecast & News

$17.61
-0.82 (-4.45 %)
(As of 12/6/2019 06:00 AM ET)
Today's Range
$17.59
Now: $17.61
$18.52
50-Day Range
$17.27
MA: $18.82
$20.74
52-Week Range
$13.90
Now: $17.61
$35.82
Volume182,983 shs
Average Volume235,777 shs
Market Capitalization$1.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Akcea Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.87 million
Book Value$3.10 per share

Profitability

Net Income$-225,820,000.00

Miscellaneous

Employees248
Market Cap$1.65 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.


Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its earnings results on Tuesday, November, 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.21. The firm had revenue of $20.62 million for the quarter, compared to analyst estimates of $22.54 million. Akcea Therapeutics had a negative return on equity of 33.00% and a negative net margin of 50.71%. The business's revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.73) EPS. View Akcea Therapeutics' Earnings History.

When is Akcea Therapeutics' next earnings date?

Akcea Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Akcea Therapeutics.

What price target have analysts set for AKCA?

4 brokerages have issued 1 year price targets for Akcea Therapeutics' shares. Their forecasts range from $24.00 to $45.00. On average, they anticipate Akcea Therapeutics' share price to reach $36.00 in the next twelve months. This suggests a possible upside of 104.4% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

What is the consensus analysts' recommendation for Akcea Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

Has Akcea Therapeutics been receiving favorable news coverage?

Headlines about AKCA stock have been trending somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akcea Therapeutics earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Akcea Therapeutics.

Who are some of Akcea Therapeutics' key competitors?

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Achaogen (AKAO), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), Apollo Global Management (APO) and Ciena (CIEN).

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the folowing people:
  • Ms. Paula Soteropoulos, CEO & Director (Age 51)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
  • Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
  • Ms. Sarah Boyce, Pres & Director (Age 47)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Who are Akcea Therapeutics' major shareholders?

Akcea Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (0.66%), Alps Advisors Inc. (0.20%), Russell Investments Group Ltd. (0.07%), Squarepoint Ops LLC (0.02%) and Barclays PLC (0.02%). Company insiders that own Akcea Therapeutics stock include Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Institutional Ownership Trends for Akcea Therapeutics.

Which institutional investors are selling Akcea Therapeutics stock?

AKCA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC and Alps Advisors Inc.. Company insiders that have sold Akcea Therapeutics company stock in the last year include Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Insider Buying and Selling for Akcea Therapeutics.

Which institutional investors are buying Akcea Therapeutics stock?

AKCA stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Barclays PLC. View Insider Buying and Selling for Akcea Therapeutics.

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $17.61.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.65 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.

What is Akcea Therapeutics' official website?

The official website for Akcea Therapeutics is http://www.akceatx.com/.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]


MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  324 (Vote Underperform)
Total Votes:  647
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel